Use of surgery and carboplatin in feline malignant mammary gland neoplasms with advanced clinical staging

Cecilia Bonolo De Campos; Fernanda Camargo Nunes; Gleidice Eunice Lavalle; Geovanni Dantas Cassali

Use of surgery and carboplatin in feline malignant mammary gland neoplasms with advanced clinical staging

In Vivo. 2014 Sep-Oct;28(5):863-6.

Authors

Cecilia Bonolo De Campos¹, Fernanda Camargo Nunes², Gleidice Eunice Lavalle³, Geovanni Dantas Cassali⁴

Affiliations

¹ Postgraduate Program of Veterinary Medicine, School of Agricultural and Veterinary Sciences of the Sao Paulo State University (FCAV/UNESP) - Jaboticabal Campus, Jaboticabal, Brazil Laboratory of Comparative Pathology, Department of General Pathology, Biological Science Institute (ICB), Department of General Pathology, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.
² Laboratory of Comparative Pathology, Department of General Pathology, Biological Science Institute (ICB), Department of General Pathology, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.
³ Veterinary Hospital, Veterinary School, Department of Veterinary Clinic and Surgery, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.
⁴ Postgraduate Program of Veterinary Medicine, School of Agricultural and Veterinary Sciences of the Sao Paulo State University (FCAV/UNESP) - Jaboticabal Campus, Jaboticabal, Brazil Laboratory of Comparative Pathology, Department of General Pathology, Biological Science Institute (ICB), Department of General Pathology, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil geovanni.cassali@gmail.com.

PMID: 25189900

Abstract

Background/aim: Feline mammary carcinomas (FMCs) are characterized by poor prognosis and little progress has been made in extending patient survival. The aim of the study was to compare overall survival periods of FMCs submitted to different treatment protocols, including surgery and adjuvant chemotherapy.

Materials and methods: Analysis of conventional surgical excision alone or in association with adjuvant chemotherapy with carboplatin in sixteen cats diagnosed with stage III and grade II or III FMCs was performed.

Results: Patients treated with surgery and chemotherapy presented a longer overall survival (OS) than those treated only with surgery, however, no statistical difference was observed when comparing both treatments (p=0.883).

Conclusion: Therapeutic benefit of carboplatin remains invalidated for FMCs and further investigation regarding adjuvant therapies are warranted. Surgery remains as the gold treatment in FMCs.

Keywords: Feline; carboplatin; chemotherapy; mammary gland; neoplasm.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / pharmacology*
Carboplatin / administration & dosage
Carboplatin / pharmacology*
Cats
Disease Models, Animal
Female
Mammary Neoplasms, Animal / mortality
Mammary Neoplasms, Animal / pathology*
Mammary Neoplasms, Animal / therapy*
Mastectomy*
Neoplasm Staging
Treatment Outcome

Substances

Antineoplastic Agents
Carboplatin